BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fisher CE, Knudsen JL, Lease ED, Jerome KR, Rakita RM, Boeckh M, Limaye AP. Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients. Clin Infect Dis 2017;65:57-63. [PMID: 28369203 DOI: 10.1093/cid/cix259] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Herrera S, Khan B, Singer LG, Binnie M, Chaparro C, Chow CW, Martinu T, Tomlinson G, Keshavjee S, Husain S, Tikkanen JM. Extending cytomegalovirus prophylaxis in high-risk (D+/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: A retrospective study. Transpl Infect Dis 2020;22:e13277. [PMID: 32170813 DOI: 10.1111/tid.13277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Griffiths PD. An explanation for posttransplant late-onset disease associated with CMV prophylaxis. Rev Med Virol 2019;29:e2080. [PMID: 31429170 DOI: 10.1002/rmv.2080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Limaye AP, Babu TM, Boeckh M. Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation. Clin Microbiol Rev 2020;34:e00043-19. [PMID: 33115722 DOI: 10.1128/CMR.00043-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
4 Majeed A, Latif A, Kapoor V, Sohail A, Florita C, Georgescu A, Zangeneh T. Resistant Cytomegalovirus Infection in Solid-organ Transplantation: Single-center Experience, Literature Review of Risk Factors, and Proposed Preventive Strategies. Transplant Proc 2018;50:3756-62. [PMID: 30586840 DOI: 10.1016/j.transproceed.2018.02.091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Van Leer Buter CC, de Voogd DWK, Blokzijl H, de Joode AAE, Berger SP, Verschuuren EAM, Niesters HGM. Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands. J Antimicrob Chemother 2019;74:2370-6. [PMID: 31093660 DOI: 10.1093/jac/dkz196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Baradhi KM, Aure RL, El-Amm JM. High-dose Valganciclovir Treatment for Resistant Cytomegalovirus Colitis due to UL97 and UL54 Mutations. Transplant Proc. 2018;50:142-144. [PMID: 29407298 DOI: 10.1016/j.transproceed.2017.11.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
7 Mullane KM. Human Cytomegalovirus Prophylaxis and Treatment in Lung Transplantation in the Current Era. Curr Pulmonol Rep 2020;9:10-27. [DOI: 10.1007/s13665-020-00246-y] [Reference Citation Analysis]
8 Okoh OA, Klahn P. Trimethyl Lock: A Multifunctional Molecular Tool for Drug Delivery, Cellular Imaging, and Stimuli-Responsive Materials. ChemBioChem 2018;19:1668-94. [DOI: 10.1002/cbic.201800269] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
9 Meesing A, Razonable RR. New Developments in the Management of Cytomegalovirus Infection After Transplantation. Drugs. 2018;78:1085-1103. [PMID: 29961185 DOI: 10.1007/s40265-018-0943-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 12.3] [Reference Citation Analysis]
10 Kaminski H, Belanger J, Mary J, Garrigue I, Acquier M, Déchanet-Merville J, Merville P, Couzi L. Effect of mTOR inhibitors during CMV disease in kidney transplant recipients: Results of a pilot retrospective study. Microbiol Immunol 2020;64:520-31. [PMID: 32249964 DOI: 10.1111/1348-0421.12794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Azimi T, Tavakolian S, Goudarzi H, Pourmand MR, Faghihloo E. Global estimate of phenotypic and genotypic ganciclovir resistance in cytomegalovirus infections among HIV and organ transplant patients; A systematic review and meta-analysis. Microb Pathog 2020;141:104012. [PMID: 32004622 DOI: 10.1016/j.micpath.2020.104012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 de Matos SB, Meyer R, Lima FWM. Cytomegalovirus Infection after Renal Transplantation: Occurrence, Clinical Features, and the Cutoff for Antigenemia in a University Hospital in Brazil. Infect Chemother 2017;49:255-61. [PMID: 29299892 DOI: 10.3947/ic.2017.49.4.255] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
13 Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, Mullane KM, Kotton C, Lundgren J, Komatsu TE, Lischka P, Josephson F, Douglas CM, Umeh O, Miller V, Ljungman P; Resistant Definitions Working Group of the Cytomegalovirus Drug Development Forum. Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. Clin Infect Dis 2019;68:1420-6. [PMID: 30137245 DOI: 10.1093/cid/ciy696] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 26.0] [Reference Citation Analysis]
14 Ivana T, Robert P, Pavel S, Lenka T, Irena K. Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells. Transpl Immunol 2022;:101539. [PMID: 35051589 DOI: 10.1016/j.trim.2022.101539] [Reference Citation Analysis]
15 Calabrese DR, Chong T, Wang A, Singer JP, Gottschall M, Hays SR, Golden JA, Kukreja J, Lanier LL, Tang Q, Greenland JR. NKG2C Natural Killer Cells in Bronchoalveolar Lavage Are Associated With Cytomegalovirus Viremia and Poor Outcomes in Lung Allograft Recipients. Transplantation 2019;103:493-501. [PMID: 30211828 DOI: 10.1097/TP.0000000000002450] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
16 Mehta Steinke SA, Alfares M, Valsamakis A, Shoham S, Arav-Boger R, Lees L, Ostrander D, Forman MS, Shedeck A, Ambinder RF, Jones RJ, Avery RK. Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection. Transpl Infect Dis 2021;23:e13521. [PMID: 33220125 DOI: 10.1111/tid.13521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Chauhan V, Singh MP. Immuno-informatics approach to design a multi-epitope vaccine to combat cytomegalovirus infection. European Journal of Pharmaceutical Sciences 2020;147:105279. [DOI: 10.1016/j.ejps.2020.105279] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
18 Lodding IP, Jørgensen M, Bennedbæk M, Kirkby N, Naegele K, Gustafsson F, Perch M, Rasmussen A, Sengeløv H, Sørensen SS, Hirsch HH, Lundgren JD. Development and Dynamics of Cytomegalovirus UL97 Ganciclovir Resistance Mutations in Transplant Recipients Detected by Next-Generation Sequencing. Open Forum Infect Dis 2021;8:ofab462. [PMID: 34660835 DOI: 10.1093/ofid/ofab462] [Reference Citation Analysis]
19 Lumley S, Green C, Rafferty H, Smith C, Harber M, O'Beirne J, Jones G, Thorburn D, Marshall A, Shah T, Zuhair M, Rothwell E, Atabani S, Haque T, Griffiths P. Cytomegalovirus viral load parameters associated with earlier initiation of pre-emptive therapy after solid organ transplantation. PLoS One 2019;14:e0210420. [PMID: 30682032 DOI: 10.1371/journal.pone.0210420] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Gelbmann CB, Kalejta RF. The Membrane-Spanning Peptide and Acidic Cluster Dileucine Sorting Motif of UL138 Are Required To Downregulate MRP1 Drug Transporter Function in Human Cytomegalovirus-Infected Cells. J Virol 2019;93:e00430-19. [PMID: 30894470 DOI: 10.1128/JVI.00430-19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Boonsathorn S, Pasomsub E, Techasaensiri C, Apiwattanakul N. Analysis of Ganciclovir-Resistant Cytomegalovirus Infection Caused by the UL97 Gene Mutation in Codons 460 and 520 in Pediatric Patients: A Case Series. Open Forum Infect Dis 2019;6:ofz480. [PMID: 32528998 DOI: 10.1093/ofid/ofz480] [Reference Citation Analysis]
22 Oiknine-Djian E, Weisblum Y, Panet A, Wong HN, Haynes RK, Wolf DG. The Artemisinin Derivative Artemisone Is a Potent Inhibitor of Human Cytomegalovirus Replication. Antimicrob Agents Chemother 2018;62:e00288-18. [PMID: 29712656 DOI: 10.1128/AAC.00288-18] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 5.8] [Reference Citation Analysis]
23 El Helou G, Razonable RR. Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation. Expert Opin Drug Saf 2019;18:1017-30. [PMID: 31478398 DOI: 10.1080/14740338.2019.1662787] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
24 Razonable RR. Drug-resistant cytomegalovirus: clinical implications of specific mutations. Current Opinion in Organ Transplantation 2018;23:388-94. [DOI: 10.1097/mot.0000000000000541] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
25 Raval AD, Kistler KD, Tang Y, Murata Y, Snydman DR. Epidemiology, risk factors, and outcomes associated with cytomegalovirus in adult kidney transplant recipients: A systematic literature review of real-world evidence. Transpl Infect Dis 2021;23:e13483. [PMID: 33012092 DOI: 10.1111/tid.13483] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
26 Igbinedion SO, Patel K, Samant H, Wellman GP. Ganciclovir-Resistant CMV Colitis in a Donor-Seronegative/Recipient-Seronegative Liver Transplant Patient. ACG Case Rep J 2018;5:e102. [PMID: 30643845 DOI: 10.14309/crj.2018.102] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 McVoy MM, Tenorio E, Kauvar LM. A Native Human Monoclonal Antibody Targeting HCMV gB (AD-2 Site I). Int J Mol Sci 2018;19:E3982. [PMID: 30544903 DOI: 10.3390/ijms19123982] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
28 Cheng WY, Avery RK, Thompson-Leduc P, Cheung HC, Bo T, Duh MS, Hirji I. Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation. J Med Econ 2022;:1-39. [PMID: 35240904 DOI: 10.1080/13696998.2022.2046388] [Reference Citation Analysis]
29 Grossi PA, Baldanti F, Andreoni M, Perno CF. CMV infection management in transplant patients in Italy. J Clin Virol 2020;123:104211. [PMID: 31879243 DOI: 10.1016/j.jcv.2019.104211] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Papanicolaou GA, Silveira FP, Langston AA, Pereira MR, Avery RK, Uknis M, Wijatyk A, Wu J, Boeckh M, Marty FM, Villano S. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study. Clin Infect Dis 2019;68:1255-64. [PMID: 30329038 DOI: 10.1093/cid/ciy706] [Cited by in Crossref: 68] [Cited by in F6Publishing: 56] [Article Influence: 34.0] [Reference Citation Analysis]
31 Carlson TJ, Gonzales-Luna AJ, Garey KW. Recent developments in antimicrobial therapy for gastrointestinal infections. Curr Opin Gastroenterol 2021;37:30-6. [PMID: 33229860 DOI: 10.1097/MOG.0000000000000696] [Reference Citation Analysis]
32 Oiknine-Djian E, Bar-On S, Laskov I, Lantsberg D, Haynes RK, Panet A, Wolf DG. Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus. Antiviral Res 2019;172:104639. [PMID: 31654672 DOI: 10.1016/j.antiviral.2019.104639] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
33 Clausen ES, Zaffiri L. Infection prophylaxis and management of viral infection. Ann Transl Med 2020;8:415. [PMID: 32355859 DOI: 10.21037/atm.2019.11.85] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
34 Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, Humar A;  The Transplantation Society International CMV Consensus Group. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018;102:900-931. [PMID: 29596116 DOI: 10.1097/tp.0000000000002191] [Cited by in Crossref: 383] [Cited by in F6Publishing: 153] [Article Influence: 127.7] [Reference Citation Analysis]
35 Sandkovsky U, Qiu F, Kalil AC, Florescu A, Wilson N, Manning C, Florescu DF. Risk Factors for the Development of Cytomegalovirus Resistance in Solid Organ Transplantation: A Retrospective Case-Control Study. Transplant Proc 2018;50:3763-8. [PMID: 30577267 DOI: 10.1016/j.transproceed.2018.08.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Cherrier L, Nasar A, Goodlet KJ, Nailor MD, Tokman S, Chou S. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. Am J Transplant 2018;18:3060-4. [PMID: 30286286 DOI: 10.1111/ajt.15135] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 17.3] [Reference Citation Analysis]
37 Khan SF, Yong MK, Slavin MA, Hughes P, Sasadeusz J. Very late‐onset cytomegalovirus disease with ganciclovir resistance >15 years following renal transplantation. Transpl Infect Dis 2021;23. [DOI: 10.1111/tid.13441] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 López-Aladid R, Guiu A, Mosquera MM, López-Medrano F, Cofán F, Linares L, Torre-Cisneros J, Vidal E, Moreno A, Aguado JM, Cordero E, Martin-Gandul C, Carratalá J, Sabé N, Niubó J, Cervera C, Capón A, Cervilla A, Santos M, Bodro M, Muñoz P, Fariñas MC, Antón A, Aranzamendi M, Montejo M, Pérez-Romero P, Len O, Marcos MÁ. Improvement in detecting cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance using next generation sequencing. PLoS One 2019;14:e0219701. [PMID: 31318908 DOI: 10.1371/journal.pone.0219701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
39 Rouphael NG, Hurwitz SJ, Hart M, Beck A, Anderson EJ, Deye G, Osborn B, Cai SY, Focht C, Amegashie C, Bowlin TL, Brooks J, Mulligan MJ. Phase Ib Trial To Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of Filociclovir (MBX-400, Cyclopropavir) in Healthy Volunteers. Antimicrob Agents Chemother 2019;63:e00717-19. [PMID: 31285228 DOI: 10.1128/AAC.00717-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
40 Yang SL, Lin TW, Lin HC, Wang HY, Chang PY, Wang PN, Yang S, Lu JJ. Molecular Epidemiology of Cytomegalovirus UL97 and UL54 variants in Taiwan. J Microbiol Immunol Infect 2021;54:971-8. [PMID: 33632621 DOI: 10.1016/j.jmii.2021.01.007] [Reference Citation Analysis]
41 Fan JJ, Tao Y, Hwang DK. Comparison of intravitreal ganciclovir monotherapy and combination with foscarnet as initial therapy for cytomegalovirus retinitis. Int J Ophthalmol 2018;11:1638-42. [PMID: 30364196 DOI: 10.18240/ijo.2018.10.10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
42 Britt WJ, Prichard MN. New therapies for human cytomegalovirus infections. Antiviral Res 2018;159:153-74. [PMID: 30227153 DOI: 10.1016/j.antiviral.2018.09.003] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 11.8] [Reference Citation Analysis]